Evaxion A/S (EVAX)

Market Cap	20.53M
Revenue (ttm)	3.18M
Net Income (ttm)	-11.97M
Shares Out	6.32M
EPS (ttm)	-4.45
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	74,153
Open	3.150
Previous Close	3.101
Day's Range	3.100 - 3.290
52-Week Range	1.200 - 17.750
Beta	0.14
Analysts	Strong Buy
Price Target	10.00 (+207.69%)
Earnings Date	Aug 14, 2025

About EVAX

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based cancer vaccine that has completed Phase 1/2a trial to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers, including non-small cell lung cancer. Its programs also include vacci...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 5, 2021
• Employees: 46
• Stock Exchange: NASDAQ
• Ticker Symbol: EVAX
• Website: https://evaxion.ai

Financial Performance

In 2024, Evaxion's revenue was $3.34 million, an increase of 4480.82% compared to the previous year's $73,000. Losses were -$10.57 million, -52.24% less than in 2023.

Analyst Summary

According to 2 analysts, the average rating for EVAX stock is "Strong Buy." The 12-month stock price target is $10.0, which is an increase of 207.69% from the latest price.

Price Target

$10.0

(207.69% upside)

Analyst Consensus: Strong Buy